Skip to main content
SpringerLink
Log in

Mycobacterium tuberculosis in Transplantation

  • Reference work entry
  • First Online:
Emerging Transplant Infections

  • 1101 Accesses

Abstract

This chapter reviews the epidemiology, clinical impact, diagnosis, prevention, and management of tuberculosis (TB) in solid organ and hematopoietic stem cell transplantation. Given the limitations of screening for latent TB using either the tuberculin skin test or interferon gamma release assays, it is important to also consider exposure history and chest imaging; promising new TB diagnostic strategies are currently under development. The clinical manifestations of active tuberculosis in transplantation are often extrapulmonary or disseminated in nature. Strategies for treatment of latent and active tuberculosis in both solid organ and hematopoietic stem cell transplantation are discussed in this chapter. The optimization of antituberculous drug dosing, treatment duration, and combinations in drug-sensitive and multidrug-resistant TB in transplantation needs further study.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 699.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 899.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40(4):581–7.

    Article  PubMed  Google Scholar 

  2. Subramanian AK, Morris MI, Practice ASTIDCo. Mycobacterium tuberculosis infections in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):68–76.

    Article  CAS  PubMed  Google Scholar 

  3. Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: impact and implications for management. Clin Infect Dis. 1998;27(5):1266–77.

    Article  CAS  PubMed  Google Scholar 

  4. Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med. 2007;13(3):290–4.

    Article  CAS  PubMed  Google Scholar 

  5. Horne DJ, Narita M, Spitters CL, Parimi S, Dodson S, Limaye AP. Challenging issues in tuberculosis in solid organ transplantation. Clin Infect Dis. 2013;57(10):1473–82.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: the rise of extensively drug-resistant tuberculosis. Nat Med. 2007;13(3):295–8.

    Article  CAS  PubMed  Google Scholar 

  7. Huaman MA, Brawley R, Ashkin D. Multidrug-resistant tuberculosis in transplant recipients: case report and review of the literature. Transpl Infect Dis. 2017;19(2)

    Google Scholar 

  8. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e95.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Aguado JM, Torre-Cisneros J, Fortun J, Benito N, Meije Y, Doblas A, et al. Tuberculosis in solid-organ transplant recipients: consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis. 2009;48(9):1276–84.

    Article  PubMed  Google Scholar 

  10. Bumbacea D, Arend SM, Eyuboglu F, Fishman JA, Goletti D, Ison MG, et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J. 2012;40(4):990–1013.

    Article  PubMed  Google Scholar 

  11. Subramanian AK, Theodoropoulos NM. Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transpl. 2019:e13513.

    Google Scholar 

  12. Currie AC, Knight SR, Morris PJ. Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation. 2010;90(7):695–704.

    Article  PubMed  Google Scholar 

  13. Vikrant S, Agarwal SK, Gupta S, Bhowmik D, Tiwari SC, Dash SC, et al. Prospective randomized control trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis. 2005;7(3–4):99–108.

    Article  CAS  PubMed  Google Scholar 

  14. Naqvi R, Akhtar S, Noor H, Saeed T, Bhatti S, Sheikh R, et al. Efficacy of isoniazid prophylaxis in renal allograft recipients. Transplant Proc. 2006;38(7):2057–8.

    Article  CAS  PubMed  Google Scholar 

  15. Torre-Cisneros J, San-Juan R, Rosso-Fernandez CM, Silva JT, Munoz-Sanz A, Munoz P, et al. Tuberculosis prophylaxis with levofloxacin in liver transplant patients is associated with a high incidence of tenosynovitis: safety analysis of a multicenter randomized trial. Clin Infect Dis. 2015;60(11):1642–9.

    Article  CAS  PubMed  Google Scholar 

  16. Kim SH, Lee SO, Park IA, Kim SM, Park SJ, Yun SC, et al. Isoniazid treatment to prevent TB in kidney and pancreas transplant recipients based on an interferon-gamma-releasing assay: an exploratory randomized controlled trial. J Antimicrob Chemother. 2015;70(5):1567–72.

    Article  CAS  PubMed  Google Scholar 

  17. Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley CL, Desmond E, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64(2):111–5.

    Article  PubMed  Google Scholar 

  18. Comstock GW. Epidemiology of tuberculosis. Am Rev Respir Dis. 1982;125(3 Pt 2):8–15.

    CAS  PubMed  Google Scholar 

  19. MacNeil A, Glaziou P, Sismanidis C, Maloney S, Floyd K. Global epidemiology of tuberculosis and Progress toward achieving global targets – 2017. MMWR Morb Mortal Wkly Rep. 2019;68(11):263–6.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation. 1996;61(2):211–5.

    Article  CAS  PubMed  Google Scholar 

  21. Jeong JC, Koo TY, Jeon HJ, Park HC, Ryu HJ, Lee JP, et al. Utility of QuantiFERON-TB assay for prediction of tuberculosis development in kidney transplant patients in an intermediate-tuberculosis-burden country: lack of evidence for enhanced prediction for short-term tuberculosis development. Transplant Proc. 2014;46(2):583–7.

    Article  CAS  PubMed  Google Scholar 

  22. Jung JY, Joo DJ, Lee CH, Park MS, Kim YS, Kim MS, et al. Pre-transplant risk factors for tuberculosis after kidney transplant in an intermediate burden area. Int J Tuberc Lung Dis. 2012;16(2):248–54.

    Article  CAS  PubMed  Google Scholar 

  23. Marques ID, Azevedo LS, Pierrotti LC, Caires RA, Sato VA, Carmo LP, et al. Clinical features and outcomes of tuberculosis in kidney transplant recipients in Brazil: a report of the last decade. Clin Transpl. 2013;27(2):E169–76.

    Article  Google Scholar 

  24. Torre-Cisneros J, Doblas A, Aguado JM, San Juan R, Blanes M, Montejo M, et al. Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish network of infection in transplantation) cohort. Clin Infect Dis. 2009;48(12):1657–65.

    Article  PubMed  Google Scholar 

  25. Abad CLR, Razonable RR. Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases. Clin Transpl. 2018:e13259.

    Google Scholar 

  26. Chen CY, Liu CJ, Feng JY, Loong CC, Liu C, Hsia CY, et al. Incidence and risk factors for tuberculosis after liver transplantation in an endemic area: a Nationwide population-based matched cohort study. Am J Transplant. 2015;15(8):2180–7.

    Article  PubMed  Google Scholar 

  27. Agrawal N, Aggarwal M, Kapoor J, Ahmed R, Shrestha A, Kaushik M, et al. Incidence and clinical profile of tuberculosis after allogeneic stem cell transplantation. Transpl Infect Dis. 2018;20(1)

    Google Scholar 

  28. Aki SZ, Sucak GT, Tunccan OG, Kokturk N, Senol E. The incidence of tuberculosis infection in hematopoietic stem cell transplantation recipients: a retrospective cohort study from a center in Turkey. Transpl Infect Dis. 2018;20(4):e12912.

    Article  PubMed  CAS  Google Scholar 

  29. Cheng MP, Kusztos AE, Bold TD, Ho VT, Glotzbecker BE, Hsieh C, et al. Risk of Latent Tuberculosis Reactivation After Hematopoietic cell Transplantation. 2019.

    Google Scholar 

  30. Liu YC, Wu CJ, Ko PS, Chien SH, Fan NW, Wang HY, et al. Mycobacterial infections in adult recipients of allogeneic hematopoietic stem cell transplantation: a cohort study in a high endemic area. J Microbiol Immunol Infect = Wei mian yu gan ran za zhi. 2018;

    Google Scholar 

  31. Fan WC, Liu CJ, Hong YC, Feng JY, Su WJ, Chien SH, et al. Long-term risk of tuberculosis in haematopoietic stem cell transplant recipients: a 10-year nationwide study. Int J Tuberc Lung Dis. 2015;19(1):58–64.

    Article  PubMed  Google Scholar 

  32. Abad CLR, Razonable RR. An update on Mycobacterium tuberculosis infection after hematopoietic stem cell transplantation in adults. Clin Transpl. 2018;32(12):e13430.

    Article  Google Scholar 

  33. Munoz L, Gomila A, Casas S, Castellote J, Arnan M, Rafecas A, et al. Immunodiagnostic Tests’ predictive values for progression to tuberculosis in transplant recipients: a prospective cohort study. Transplant Direct. 2015;1(3):e12.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Kim SH, Lee SO, Park JB, Park IA, Park SJ, Yun SC, et al. A prospective longitudinal study evaluating the usefulness of a T-cell-based assay for latent tuberculosis infection in kidney transplant recipients. Am J Transplant. 2011;11(9):1927–35.

    Article  PubMed  Google Scholar 

  35. Kay A, Barry PM, Annambhotla P, Greene C, Cilnis M, Chin-Hong P, et al. Solid organ transplant-transmitted tuberculosis linked to a community outbreak – California, 2015. MMWR Morb Mortal Wkly Rep. 2017;66(30):801–5.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kumar D, Budev M, Koval C, Hellinger WC, Gordon SM, Tomford JW. Donor-derived tuberculosis (TB) infection in lung transplant despite following recommended algorithm. Am J Transplant. 2013;13(8):2225–6.

    Article  CAS  PubMed  Google Scholar 

  37. Morris MI, Daly JS, Blumberg E, Kumar D, Sester M, Schluger N, et al. Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant. 2012;12(9):2288–300.

    Article  CAS  PubMed  Google Scholar 

  38. Jereb JA, Burwen DR, Dooley SW, Haas WH, Crawford JT, Geiter LJ, et al. Nosocomial outbreak of tuberculosis in a renal transplant unit: application of a new technique for restriction fragment length polymorphism analysis of Mycobacterium tuberculosis isolates. J Infect Dis. 1993;168(5):1219–24.

    Article  CAS  PubMed  Google Scholar 

  39. Guirao-Arrabal E, Santos F, Redel-Montero J, Vaquero JM, Cantisan S, Vidal E, et al. Risk of tuberculosis after lung transplantation: the value of pretransplant chest computed tomography and the impact of mTOR inhibitors and azathioprine use. Transpl Infect Dis. 2016;18(4):512–9.

    Article  CAS  PubMed  Google Scholar 

  40. Torres J, Aguado JM, San Juan R, Andres A, Sierra P, Lopez-Medrano F, et al. Hepatitis C virus, an important risk factor for tuberculosis in immunocompromised: experience with kidney transplantation. Transpl Int. 2008;21(9):873–8.

    Article  PubMed  Google Scholar 

  41. Lee HJ, Lee DG, Choi SM, Park SH, Cho SY, Choi JK, et al. The demanding attention of tuberculosis in allogeneic hematopoietic stem cell transplantation recipients: high incidence compared with general population. PLoS One. 2017;12(3):e0173250.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Sloot R, Schim van der Loeff MF, Kouw PM, Borgdorff MW. Risk of tuberculosis after recent exposure. A 10-year follow-up study of contacts in Amsterdam. Am J Respir Crit Care Med. 2014;190(9):1044–52.

    Article  PubMed  Google Scholar 

  43. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364(15):1441–8.

    Article  CAS  PubMed  Google Scholar 

  44. Giacomelli IL, Schuhmacher Neto R, Nin CS, Cassano PS, Pereira M, Moreira JDS, et al. High-resolution computed tomography findings of pulmonary tuberculosis in lung transplant recipients. J Bras Pneumol. 2017;43(4):270–3.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Schuhmacher Neto R, Giacomelli IL, Schuller Nin C, da Silva Moreira J, Comaru Pasqualotto A, Marchiori E, et al. High-resolution CT findings of pulmonary tuberculosis in liver transplant patients. Clin Radiol. 2017;72(10):899 e9–e14.

    Article  Google Scholar 

  46. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis. 2010;12(2):106–12.

    Article  CAS  PubMed  Google Scholar 

  47. Abad CLR, Razonable RR. Donor derived Mycobacterium tuberculosis infection after solid-organ transplantation: a comprehensive review. Transpl Infect Dis. 2018;20(5):e12971.

    Article  PubMed  CAS  Google Scholar 

  48. Holty JE, Sista RR. Mycobacterium tuberculosis infection in transplant recipients: early diagnosis and treatment of resistant tuberculosis. Curr Opin Organ Transplant. 2009;14(6):613–8.

    Article  PubMed  Google Scholar 

  49. Pfyffer GE, Welscher HM, Kissling P, Cieslak C, Casal MJ, Gutierrez J, et al. Comparison of the mycobacteria growth Indicator tube (MGIT) with radiometric and solid culture for recovery of acid-fast bacilli. J Clin Microbiol. 1997;35(2):364–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Bartoletti M, Martelli G, Tedeschi S, Morelli M, Bertuzzo V, Tadolini M, et al. Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. Transpl Infect Dis. 2017;19(2)

    Google Scholar 

  51. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, et al. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection – United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25.

    PubMed  Google Scholar 

  52. Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Schafers HJ, et al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009;34(3):702–10.

    Article  CAS  PubMed  Google Scholar 

  53. Casas S, Munoz L, Moure R, Castellote J, Guerra MR, Gonzalez L, et al. Comparison of the 2-step tuberculin skin test and the quantiFERON-TB gold in-tube test for the screening of tuberculosis infection before liver transplantation. Liver Transpl. 2011;17(10):1205–11.

    Article  PubMed  Google Scholar 

  54. Hand J, Sigel K, Huprikar S, Hamula C, Rana M. Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON((R)) -TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant. Transpl Infect Dis. 2018;20(2):e12845.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  55. Lyu J, Lee SG, Hwang S, Lee SO, Cho OH, Chae EJ, et al. Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver Transpl. 2011;17(8):963–8.

    Article  PubMed  Google Scholar 

  56. Munoz L, Santin M. Prevention and Management of Tuberculosis in transplant recipients: from guidelines to clinical practice. Transplantation. 2016;100(9):1840–52.

    Article  CAS  PubMed  Google Scholar 

  57. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009;15(10):1143–238.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Manson AL, Abeel T, Galagan JE, Sundaramurthi JC, Salazar A, Gehrmann T, et al. Mycobacterium tuberculosis whole genome sequences from southern India suggest novel resistance mechanisms and the need for region-specific diagnostics. Clin Infect Dis. 2017;64(11):1494–501.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Broger T, Tsionksy M, Mathew A, Lowary TL, Pinter A, Plisova T, et al. Sensitive electrochemiluminescence (ECL) immunoassays for detecting lipoarabinomannan (LAM) and ESAT-6 in urine and serum from tuberculosis patients. PLoS One. 2019;14(4):e0215443.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Fernandez-Carballo BL, Broger T, Wyss R, Banaei N, Denkinger CM. Toward the development of a circulating free DNA-based in vitro diagnostic test for infectious diseases: a review of evidence for tuberculosis. J Clin Microbiol. 2019;57(4)

    Google Scholar 

  61. Warsinske H, Vashisht R, Khatri P. Host-response-based gene signatures for tuberculosis diagnosis: a systematic comparison of 16 signatures. PLoS Med. 2019;16(4):e1002786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Warsinske HC, Rao AM, Moreira FMF, Santos PCP, Liu AB, Scott M, et al. Assessment of validity of a blood-based 3-gene signature score for progression and diagnosis of tuberculosis, disease severity, and treatment response. JAMA Netw Open. 2018;1(6):e183779.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med. 2006;174(10):1153–8.

    Article  PubMed  Google Scholar 

  64. McGregor MM, Olliaro P, Wolmarans L, Mabuza B, Bredell M, Felten MK, et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med. 1996;154(5):1462–7.

    Article  CAS  PubMed  Google Scholar 

  65. Lopez-Montes A, Gallego E, Lopez E, Perez J, Lorenzo I, Llamas F, et al. Treatment of tuberculosis with rifabutin in a renal transplant recipient. Am J Kidney Dis. 2004;44(4):e59–63.

    Article  PubMed  Google Scholar 

  66. Regazzi M, Carvalho AC, Villani P, Matteelli A. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet. 2014;53(6):489–507.

    Article  CAS  PubMed  Google Scholar 

  67. Cohen K, Meintjes G. Management of individuals requiring antiretroviral therapy and TB treatment. Curr Opin HIV AIDS. 2010;5(1):61–9.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Vachharajani TJ, Oza UG, Phadke AG, Kirpalani AL. Tuberculosis in renal transplant recipients: rifampicin sparing treatment protocol. Int Urol Nephrol. 2002;34(4):551–3.

    Article  CAS  PubMed  Google Scholar 

  69. Jha V, Sakhuja V, Gupta D, Krishna VS, Chakrabarti A, Joshi K, et al. Successful management of pulmonary tuberculosis in renal allograft recipients in a single center. Kidney Int. 1999;56(5):1944–50.

    Article  CAS  PubMed  Google Scholar 

  70. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1–12.

    Article  CAS  PubMed  Google Scholar 

  71. Jung BH, Park JI, Lee SG. Urgent living-donor liver transplantation in a patient with concurrent active tuberculosis: a case report. Transplant Proc. 2018;50(3):910–4.

    Article  PubMed  Google Scholar 

  72. Regmi A, Singh P, Harford A. A case of multidrug-resistant monoarticular joint tuberculosis in a renal transplant recipient. Transplant Proc. 2014;46(1):274–7.

    Article  CAS  PubMed  Google Scholar 

  73. Garcia-Goez JF, Munera GA, Rojas V, Pacheco R, Cayla JA, Miro JM. Tuberculosis in recipients of solid-organ transplants during 1995–2015 in Cali, Colombia. Int J Tuberc Lung Dis. 2017;21(11):1155–9.

    Article  CAS  PubMed  Google Scholar 

  74. Gumbo T, Alffenaar JC. Pharmacokinetic/Pharmacodynamic background and methods and scientific evidence base for dosing of second-line tuberculosis drugs. Clin Infect Dis. 2018;67(suppl_3):S267–s73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Schluger LK, Sheiner PA, Jonas M, Guarrera JV, Fiel IM, Meyers B, et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med. 1996;63(5–6):364–9.

    CAS  PubMed  Google Scholar 

  76. Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, et al. A trial of a shorter regimen for rifampin-resistant tuberculosis. N Engl J Med. 2019;380(13):1201–13.

    Article  CAS  PubMed  Google Scholar 

  77. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005;172(9):1169–227.

    Article  Google Scholar 

  78. Getahun H, Matteelli A, Abubakar I, Aziz MA, Baddeley A, Barreira D, et al. Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries. Eur Respir J. 2015;46(6):1563–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Holty JE, Gould MK, Meinke L, Keeffe EB, Ruoss SJ. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009;15(8):894–906.

    Article  PubMed  Google Scholar 

  80. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA. 2005;293(22):2776–84.

    Article  CAS  PubMed  Google Scholar 

  81. Menzies D, Al Jahdali H, Al Otaibi B. Recent developments in treatment of latent tuberculosis infection. Indian J Med Res. 2011;133:257–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  82. Jafri SM, Singal AG, Kaul D, Fontana RJ. Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl. 2011;17(3):306–14.

    Article  PubMed  Google Scholar 

  83. Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transpl. 1997;11(1):34–7.

    CAS  Google Scholar 

  84. Singh N, Wagener MM, Gayowski T. Safety and efficacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation. 2002;74(6):892–5.

    Article  CAS  PubMed  Google Scholar 

  85. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation. 2007;83(12):1557–62.

    Article  CAS  PubMed  Google Scholar 

  86. Aspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, et al. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax. 2010;65(7):582–7.

    Article  PubMed  Google Scholar 

  87. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379(5):440–53.

    Article  CAS  PubMed  Google Scholar 

  88. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365(23):2155–66.

    Article  CAS  PubMed  Google Scholar 

  89. Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI. Twelve-week Rifapentine plus isoniazid versus 9-month isoniazid for the treatment of latent tuberculosis in renal transplant candidates. Transplantation. 2017;101(6):1468–72.

    Article  CAS  PubMed  Google Scholar 

  90. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One month of Rifapentine plus isoniazid to prevent HIV-related tuberculosis. N Engl J Med. 2019;380(11): 1001–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Chitnis AS, Schecter GF, Cilnis M, Robsky K, Flood JM, Barry PM. Epidemiology of tuberculosis cases with end-stage renal disease, California, 2010. Am J Nephrol. 2014;39(4): 314–21.

    Article  PubMed  Google Scholar 

  92. Guirao-Arrabal E, Santos F, Redel J, Vaquero JM, Torre-Cisneros J. Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. Clin Transpl. 2017;31(3)

    Google Scholar 

  93. Moon HH, Park SY, Kim JM, Park JB, Kwon CHD, Peck KR, et al. Isoniazid prophylaxis for latent tuberculosis infections in liver transplant recipients in a tuberculosis-endemic area. Ann Transplant. 2017;22:338–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Van Der Meeren O, Hatherill M, Nduba V, Wilkinson RJ, Muyoyeta M, Van Brakel E, et al. Phase 2b controlled trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2018;379(17):1621–34.

    Article  Google Scholar 

  95. Centers for Disease Control and Prevention: division of tuberculosis elimination. Latent tuberculosis infection: a guide for primary health care providers, treatment of latent TB infection 2016 updated August 5, 2016. Available from: http://www.cdc.gov/tb/publications/ltbi/treatment.htm

  96. Spyridis NP, Spyridis PG, Gelesme A, Sypsa V, Valianatou M, Metsou F, et al. The effectiveness of a 9-month regimen of isoniazid alone versus 3- and 4-month regimens of isoniazid plus rifampin for treatment of latent tuberculosis infection in children: results of an 11-year randomized study. Clin Infect Dis. 2007;45(6):715–22.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, CA, USA

    Aruna K. Subramanian

Authors
  1. Aruna K. Subramanian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Aruna K. Subramanian .

Editor information

Editors and Affiliations

  1. Immunocompromised Host Service Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

  2. Transplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

    Camille Nelson Kotton

  3. Division of Infectious Diseases, Duke University School of Medicine, Durham, NC, USA

    Cameron R. Wolfe

Section Editor information

  1. Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA

    Michele I. Morris

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Subramanian, A.K. (2021). Mycobacterium tuberculosis in Transplantation. In: Morris, M.I., Kotton, C.N., Wolfe, C.R. (eds) Emerging Transplant Infections. Springer, Cham. https://doi.org/10.1007/978-3-030-25869-6_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-25869-6_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-25868-9

  • Online ISBN: 978-3-030-25869-6

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation